HALO - CIK 0001159036
HALOZYME THERAPEUTICS, INC. trades as HALO and has a market capitalization of $8.36 B, making it the #1040 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $1.40B, up 37.6% from the prior year and net income of $316.89M. This page tracks HALOZYME THERAPEUTICS, INC. through 1,481 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 9 fiscal years HALOZYME THERAPEUTICS, INC.'s revenue grew from $146.69M to $1.40B, a compound annual growth rate of 28.5%. Net profit margin expanded from -70.2% to 22.7% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Insider sale notice | 144 | 2026-05-15 |
| Insider trade | 4 | 2026-05-13 |
| Insider sale notice | 144 | 2026-05-11 |
| Quarterly report | 10-Q | 2026-05-11 |
| Major company event | 8-K | 2026-05-11 |
| Insider trade | 4 | 2026-05-07 |
| Insider trade | 4 | 2026-05-07 |
| Insider trade | 4 | 2026-05-07 |
Comparison Medicare Expenditure for SC versus IV Drugs
Comparison Medicare Expenditure for SC versus IV Drugs
Comparison Medicare Expenditure for SC versus IV Drugs
Comparison Medicare Expenditure for SC versus IV Drugs
Comparison Medicare Expenditure for SC versus IV Drugs
The largest companies sharing HALOZYME THERAPEUTICS, INC.'s SEC industry classification (biological products, (no diagnostic substances)).
HALOZYME THERAPEUTICS, INC. (HALO) has a market capitalization of $8.36 B as of 2026-06-10, ranking #1040 among US-listed companies.
HALOZYME THERAPEUTICS, INC. reported revenue of $1.40B for fiscal year 2025, an increase of 37.6% year over year.
Yes. HALOZYME THERAPEUTICS, INC. reported net income of $316.89M in its latest fiscal year.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.